Insulet Corp. shares fell about 6.9% following a voluntary correction announcement for its Omnipod 5 insulin pods, which have a design defect causing insulin leakage. This defect has been linked to eighteen serious adverse events, including hospitalizations and diabetic ketoacidosis, affecting roughly 1.5% of annual pod production. The company disclosed the issue in an 8-K filing on March 12, 2026, but did not mention these serious events in its prior earnings call. Legal investigations are underway to determine if Insulet executives were aware of the defect earlier. This development raises concerns about product safety and company transparency.
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
